Sangamo Therapeutics rises after FDA clears application to start trial for pain treatment
20/11/2024 10:55
** Shares of genomic medicine company Sangamo Therapeutics
SGMO.O rise 12.24% to $2.20 premarket
** Co says U.S. Food and Drug Administration has cleared
co's application to start human trial for ST-503
** SGMO plans to initiate enrollment of patients in the
early-to-mid stage study for ST-503 in mid-2025
** The therapy ST-503 is being studied for the treatment of
intractable pain due to idiopathic small fiber neuropathy
(iSFN), a type of chronic nerve pain
** Up to last close, stock had more than tripled YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))